Sign Out
Hydration status: Care should be taken to maintain adequate hydration in patients receiving higher dose oral regimens e.g. for the treatment of herpes zoster infection (4g daily), in order to avoid the risk of possible renal toxicity.
The results of a wide range of mutagenicity tests in vitro and in vivo indicate that aciclovir is unlikely to pose a genetic risk to man. Aciclovir was not found to be carcinogenic in long term studies in the rat and the mouse. Largely reversible adverse effects on spermatogenesis in association with overall toxicity in rats and dogs have been reported only at doses of aciclovir greatly in excess of those employed therapeutically. Two generation studies in mice did not reveal any effect of aciclovir on fertility.
The data currently available from clinical studies is not sufficient to conclude that treatment with Herpevex reduces the incidence of chickenpox-associated complications in immunocompetent patients.
